BioSpace News Archive

Lexaria Bioscience Corp. is pleased to announce that its recent oral tetrahydrocannabinol absorption study THC-A21-1 revealed that DehydraTECH TM -THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a clinical collaboration to evaluate elzovantinib.

Research published today in the journal Frontiers in Medicine found that Gazelle™, a diagnostic platform from Hemex Health, has 99% accuracy in diagnosing sickle cell disease (SCD).

Baxter to Present at Credit Suisse 30 th Annual Virtual Healthcare Conference

Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2021 financial results on Wednesday, November 3rd , before the market opens.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share.

René Salazar has joined the Broad Institute of MIT and Harvard as its chief equity officer, a newly created position.

Biofidelity, a pioneer in precision cancer diagnostics, praised California Governor Gavin Newsom and the California legislature for the October 6th passage of SB 535, a bill that prohibits health care insurers that already cover biomarker testing from requiring prior authorization for patients with advanced stage cancer.